Literature DB >> 25125966

Osteosarcoma in an adolescent previously treated for Hodgkin's Disease.

M Kourti1, V Sidi1, E Papakonstantinou1.   

Abstract

Entities:  

Keywords:  Hodgkin’s disease; Second malignancy; childhood; osteosarcoma

Year:  2014        PMID： 25125966      PMCID： PMC4103057     

Source DB:  PubMed          Journal:  Hippokratia        ISSN： 1108-4189            Impact factor:   0.471


× No keyword cloud information.
  5 in total

1.  SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients.

Authors:  Marie-Cécile Le Deley; Jean-Marc Guinebretière; Jean-Claude Gentet; Hélène Pacquement; Fabienne Pichon; Perrine Marec-Bérard; Natacha Entz-Werlé; Claudine Schmitt; Laurence Brugières; Daniel Vanel; Noëlle Dupoüy; Marie-Dominique Tabone; Chantal Kalifa
Journal:  Eur J Cancer       Date:  2007-01-30       Impact factor: 9.162

Review 2.  Osteosarcoma.

Authors:  J Ritter; S S Bielack
Journal:  Ann Oncol       Date:  2010-10       Impact factor: 32.976

3.  Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.

Authors:  P Carde; A Hagenbeek; M Hayat; M Monconduit; J Thomas; M J Burgers; E M Noordijk; A Tanguy; J H Meerwaldt; R Le Fur
Journal:  J Clin Oncol       Date:  1993-11       Impact factor: 44.544

4.  Secondary sarcomas in childhood cancer survivors: a report from the Childhood Cancer Survivor Study.

Authors:  Tara O Henderson; John Whitton; Marilyn Stovall; Ann C Mertens; Pauline Mitby; Debra Friedman; Louise C Strong; Sue Hammond; Joseph P Neglia; Anna T Meadows; Leslie Robison; Lisa Diller
Journal:  J Natl Cancer Inst       Date:  2007-02-21       Impact factor: 11.816

5.  Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study.

Authors:  A C Mertens; Y Yasui; J P Neglia; J D Potter; M E Nesbit; K Ruccione; W A Smithson; L L Robison
Journal:  J Clin Oncol       Date:  2001-07-01       Impact factor: 50.717
  5 in total
  2 in total

1.  Triptolide reduces the viability of osteosarcoma cells by reducing MKP-1 and Hsp70 expression.

Authors:  Lei Zhao; B O Jiang; Dong Wang; Wei Liu; Huawu Zhang; Weisheng Liu; Zhen Qiu
Journal:  Exp Ther Med       Date:  2016-03-15       Impact factor: 2.447

2.  MicroRNA-144 inhibits the proliferation, apoptosis, invasion, and migration of osteosarcoma cell line F5M2.

Authors:  Shao-Qian Cui; Huan Wang
Journal:  Tumour Biol       Date:  2015-04-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.